



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/580,989	03/29/2007	Yuichi Ono	082368-008100US	5847

20350 7590 03/23/2010
TOWNSEND AND TOWNSEND AND CREW, LLP
TWO EMBARCADERO CENTER
EIGHTH FLOOR
SAN FRANCISCO, CA 94111-3834

EXAMINER

KOLKER, DANIEL E

ART UNIT	PAPER NUMBER
----------	--------------

1649

MAIL DATE	DELIVERY MODE
-----------	---------------

03/23/2010

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No. 10/580,989	Applicant(s) ONO ET AL.	
	Examiner DANIEL KOLKER	Art Unit 1649	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 06 January 2010.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1,9-12 and 27-31 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☒ Claim(s) 27-31 is/are allowed.
- 6) ☒ Claim(s) 1,9-12 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|---|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

Art Unit: 1649

DETAILED ACTION

1. The remarks and amendments filed 6 January 2010 have been entered. Claims 1, 9-12, and 27-31 are pending and under examination.

Withdrawn Rejections and Objections

2. The following rejections and objections set forth in the previous office action have been withdrawn:

A. The rejection under 35 USC 112, second paragraph is withdrawn in light of the amendments which clarify the scope of patent protection sought.

B. The rejection under 35 USC 112, first paragraph is withdrawn in light of the amendments which delete the language the examiner had considered not to be fully described.

C. The rejection of claims 3-4 under 35 USC 102(b) over Millonig is moot as the claims are canceled.

Rejections Maintained

Claim Rejections - 35 USC § 102

3. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1 and 9 are rejected under 35 U.S.C. 102(b) as being anticipated by Smidt 2000 (Nature Neuroscience 3:337-341).

This rejection stands for the reasons previously made of record and explained in further detail below. Smidt teaches nucleic acids encoding Lmx1b, as well as methods of using same. The nucleic acid is a fragment of rat Lmx1b, and encodes an amino acid that is 100% identical to the amino acids encoded by mouse Lmx1b with GenBank accession number AF078166; see p. 337 second column first paragraph. The nucleic acid used by Smidt was 115 bp long, as encompassed by claims 1 and 9. Although the nucleic acids identified by SEQ ID NO: in independent claims 1 and 9 are not identical to those disclosed by Smidt, the claims do not require identity. The claims are considerably broader, in that they are drawn to methods of using nucleic acids that hybridize to SEQ ID NO:13, 15, or 17, or nucleic acids that hybridize to

Art Unit: 1649

nucleic acids encoding SEQ ID NO:14, 16, or 18. The alignments shown below indicates that AF078166, i.e. the nucleic acid encoded by Smidt's cDNA, will hybridize to any of SEQ ID NO:13, 15, or 17. In the alignments, the top line is the nucleic acids sequence from the present application, and the bottom line is AF078166. Given the long stretches of identity across the entirety of the sequences, the nucleic acids from Smidt will inherently hybridize to SEQ ID NO:13, 15, and 17.

SEQ ID NO:13 aligned with AF078166

Qy	220	ATGTTGGACGGCCTGAAGATGGAGGAGAACTTTCAAAGTGCGATTGAGACCTCGGCATCT	279
Db	1	ATGTTGGACGGCATCAAGATGGAGGAGCAC-----GCCCTT-CGCCCCGGGC--CC	48
Qy	280	TTCTCCTCT-----TTGCTGGGCAGAGCGGTGAGCCC---CAAGTCTGTCTGCGAGG	328
Db	49	GCCACC-CTGGGGGTGCTGCTGGGCT---CCGACTGCCCGCATCCCG-CCGTCTGCGAGG	103
Qy	329	GCTGTCAGCGGGTCATCTCGGACAGGTTTCTGCTGCGGCTCAACGACAGCTTCTGGCACG	388
Db	104	GCTGCCAGCGGCCCATCTCCGACCGCTTCTGATGCGAGTCAACGAGTCGTCTGGCACG	163
Qy	389	AGCAATGCGTGCAGTGTGCCTCCTG-CAAAGAGCCCCTGGAGACCACCTGCTTCTACCGG	447
Db	164	AGGAGTGTGTTGCAGTGC GCGGCATGT CAGCAAG-CCCTCACCACCAGCTGCTACTTCCGG	222
Qy	448	GACAAGAAGCTCTACTGCAAGTACCACTACGAGAACTGTTTGCTGTCAAATGTGGGGGC	507
Db	223	GATCGGAAACTGTACTGCAAACAAGACTACCAACAGCTCTTCGCGGCAAAGTGCAGCGGC	282
Qy	508	TGCTTCGAGGCCATTGCGCCAATGAGTTTGTCTATGCGTGCCGAGAAGAGCGTATACCAC	567
Db	283	TGCATGGAGAAGATCGCGCTACCGAGTTCGTCTATGCGGGCGCTGGAGTGTGTGTACCAC	342
Qy	568	CTGAGCTGCTTCTGCTGCTGCGTCTGTGAGCGACAGCTGCAGAAGGGTGACGAGTTTGTG	627
Db	343	TTGGGCTGTTTCTGCTGCTGTGTGTGCGAGAGGCAACTGCGCAAGGGGGACGAGTTCGTG	402
Qy	628	CTGAAGGAGGGCCAGCTGCTCTGCAAAGGGGACTATGAGAAAGAACGGGAGCTGCTGAGC	687
Db	403	CTCAAGGAGGGCCAGCTGCTGTGCAAGGGTGACTATGAGAAGGAGAAAGACCTGCTCAGC	462
Qy	688	CTGGTGAGCCCTGCGGCCTCAGACTCAGGCAAAAGCGATGATGAGGA--GAGCCTTTGCA	745
Db	463	TCCGTGAGCCCGGACGAGTCTGACTCTGTGAAGAGTGAGGATGAAGATGGAGACATG--A	520
Qy	746	AGTCAGCCCATGGGGCAG-----GAAAAGGAGCATCAGAG--GACGGCAAGGACCAT	795
Db	521	AGCCCG-CCAAGGGGCAGGGCAGCCAGAGTAAGGCAAGTGGAGATGACGGGAAAGACCCG	579

Art Unit: 1649

Qy	796	AAGCGACCCAAACGTC	CCCAAGAACCATCTG	ACCACCTCAGCAGAG	GAGAGCATTTCAAGGCC	855
Db	580	AGAAGGCCCAAACGG	CCCCGAACCATCTC	ACCACACAGCAGCG	AAGAGCTTTCAAGGCA	639
Qy	856	TCGTTTGAAGTATCCT	CCAAGCCCTGCAGAA	AGGTGAGGGAGACTC	TGGCTGCGGAGACA	915
Db	640	TCCTTTGAGGTCTCCT	CCAAGCCCTGTGCGA	AGGTCCGAGAGACAT	TGGCAGCAGAGACA	699
Qy	916	GGGCTGAGTGTCCGT	GTGGTTCAGGTGTGG	TTCAGAACCCAGCG	AGCCAAGATGAAGAAG	975
Db	700	GGCCTCAGCGTGCGT	GTGGTCCAGGTCTGG	TTTCAGAACCAAAG	AGCAAAGATGAAGAAG	759
Qy	976	CTGGCCCCGGCGAC	AGCAGCAACAGCAAC	AGGACCAACAGAAC	ACCCAGAGGCTGACTT	1035
Db	760	CTGGCCCCGAGACAC	CAGCAACAG---CAG	GAGCAGCAGAACTCC	CAGCGGCTG-----	810
Qy	1036	GCTCAGACAAATGGT	AGTAGTGGGAATGCG	GGGCATGGAAGGGAT	CATGAACCCCTATACA	1095
Db	811	----GGCCAAGAGGT	TCTGTCAAGCC--GC	ATGGAGGGCATGATGG	CCCTCTACACCGCG	864
Qy	1096	TTGCCCACCCACAGC	AGCTGC---TGGCCAT	TGAACAGAGCGTCTAC	---AACTCTGAT	1149
Db	865	CTGGCCCCCTCCGC	AGCAGCAGATCGTGG	CCATGGAGCAGAGCCC	TACGGAAGCAGCGAC	924
Qy	1150	CCCTTCCGACAGGGT	CTCACCCCACCCAGAT	GCCTGGAGATCACATG	CACCCCCTATGGT	1209
Db	925	CCCTTCCAACAGGGC	CTCACGCCGCCCAAAT	TGCCAGG-GAACG----	ACTCC-----	972
Qy	1210	GCTGAACCTCTTTTT	CCATGACTTGGATAGT	GATGACACATCTCTC	AGTAACCTGGGAGAC	1269
Db	973	-----ATCTTCCAC	GATATTGATAGTGAT---	ACCTCCCTCACCAGCC	TACGCGAC	1020
Qy	1270	TGCTTCCTGGCAACCT	CAGAAGCTGGGC-CCCT	GCAGTCCAGAGTGGG	AAACCCCATTTGA	1328
Db	1021	TGCTTCCTCGGCTCTT	CCGACG-TGGGCTCCCT	TGCAGGCGCGGTGGG	GAACCCCATTTGA	1079
Qy	1329	CCATCTGTACTCCATG	CAGAATTCCTATTTCA	CCCTCTTGA	1368	
Db	1080	CCGGCTCTACTCCATG	CAGAGCTCCTACTTTG	CCCTCTTGA	1119	

SEQ ID NO:15 aligned with AF078166

Qy	222	ATGCTGGACGGCCTAAAGATGGAGGAGAAGTTCCAAAGCGCGATCGACACCTCGGCCTCC	281
Db	1	ATGTTGGACGGCATCAAGATGGAGGAGCACGCCCTTCGCCC---CGGGCCC---GCCACC	54
Qy	282	TTCTCCTCGCTGCTGGGCAGAGCGGTGAGCCC----CAAGTCTGTCTGCGAGGGCTGTCA	337
Db	55	CTGGGGGTGCTGCTGGGCT---CCGACTGCCCCGCATCCCG-CCGTCTGCGAGGGCTGCCA	110
Qy	338	GCGGGTCATCTTGACAGGTTTTCTGCTGCGGCTCAACGACAGCTTCTGGCATGAGCAGTG	397
Db	111	GCGGCCCATCTCCGACCGCTTCCTGATGCGAGTCAACGAGTCGTCTCTGGCACGAGGAGTG	170
Qy	398	CGTGCAGTGCGCCTCCTG-CAAAGAGCCCCCTGGAGACCACCTGCTTCTACCGGGACAAGA	456
Db	171	TTTGCAGTGCGCGGCATGTCAAG-CCCTCACCACCAGCTGCTACTTCCGGGATCGGA	229
Qy	457	AGCTGTACTGCAAGTATGACTACGAGAAGCTGTTTGCTGTTAAATGTGGGGGCTGCTTCG	516
Db	230	AAGTGTACTGCAACAAGACTACCAACAGCTCTTCGCGGCAAAGTGCAGCGGCTGCATGG	289
Qy	517	AGGCCATCGCTCCCAATGAGTTTGTTATGCGGGCCCAGAAGAGTGTATAACCACCTGAGCT	576
Db	290	AGAAGATCGCGCCTACCGAGTTCGTTCATGCGGGCGCTGGAGTGTGTGTACCACTTGGGCT	349
Qy	577	GCTTCTGCTGCTGTGTCTGCGAGCGACAGCTTCAGAAGGGTGATGAGTTTGTCTGAAGG	636
Db	350	GTTTCTGCTGCTGTGTGTGCGAGAGGCAACTGCGCAAGGGGGACGAGTTCGTGCTCAAGG	409
Qy	637	AGGGGCAGCTGCTCTGCAAAGGGGACTATGAGAAGGAGCGGGAGCTGCTCAGCCTGGTGA	696
Db	410	AGGGCCAGCTGCTGTGCAAGGGTGACTATGAGAAGGAGAAAGACCTGCTCAGCTCCGTGA	469
Qy	697	GCCCAGCAGCCTCAGACTCAGGTAAAAGTGATGATGAAGAAAGTCTCTGCAAGTCAGCCC	756
Db	470	GCCCGGACGAGTCTGACTCTGTGAAGAGTGAGGATGAAGATGGAGACATGAAGCCGG-CC	528
Qy	757	ATGGGGCAGGG-----AAAGGAACTGCTGAGGAAGGCAAGGACCATAAGCGCCCC	806
Db	529	AAGGGGCAGGGCAGCCAGAGTAAGGCAGTGAGATGACGGGAAAGACCCGAGAAGGCC	588
Qy	807	AAACGTCCGAGAACCATCTTGACAACTCAACAGAGGCGAGCATTCAAGGCCTCATTTGAA	866
Db	589	AAACGGCCCCGAACCATCCTCACACACAGCAGCGAAGAGCTTTCAAGGCATCCTTTGAG	648
Qy	867	GTATCCTCCAAGCCCTGCAGGAAGGTGAGAGAGACTCTGGCTGCAGAGACAGGGCTGAGT	926
Db	649	GTCTCTCCAAGCCCTGTCGGAAGGTCCGAGAGACATTGGCAGCAGAGACAGGCCTCAGC	708
Qy	927	GTCCGTGTCGTCCAGGTGTGGTTTCCAAAACCAGAGAGCGAAGATGAAGAAGCTGGCCAGG	986

Art Unit: 1649

Db	709	GTGCGTGTGGTCCAGGTCTGGTTTCAGAACCAAAGAGCAAAGATGAAGAAGCTGGCCCCG	768
Qy	987	CGACAGCAGCAGCAGCAGCAAGATCAGCAGAACACCCAGAGGCTGAGCTCTGC---TCAG	1043
Db	769	AGACACCAGCAACAGCAG---GAGCAGCAGAACTCCCAGCGGCTGGGCCAAGAGGTTCTG	825
Qy	1044	ACAAACGGTGGTGGGAGTGCTGGGATGGAAGGAATCATGAACCCCTACACGGCTCTGCCC	1103
Db	826	TCAAGC-----CGC----ATGGAGGGCATGATGGCCTCCTACACGCGCTGGCC	870
Qy	1104	ACCCACAGCAGC---TCCTGGCCATCGAGCAGAGTGTCTAC---AGCTCAGATCCCTTC	1157
Db	871	CCTCCGCAGCAGCAGATCGTGGCCATGGAGCAGAGCCCCTACGGAAGCAGCGACCCCTTC	930
Qy	1158	CGACAGGGTCTCACCCACCCCAGATGCCTGGAGACCACATGCACCCTTATGGTGCCGAG	1217
Db	931	CAACAGGGCCTCACGCCGCCCAAATGCCAGGGAACGACT-----	970
Qy	1218	CCCCTTTTCCATGACCTGGATAGCGACGACACCTCCCTCAGTAACCTGGGTGATTGTTTC	1277
Db	971	-CCATCTTCCACGATATTGATAG---TGATACCTCCCTCACCAGCCTCAGCGACTGCTTC	1026
Qy	1278	CTAGCAACCTCAGAAGCTGGGC-CTCTGCAGTCCAGAGTGGGAAACCCATTGACCATCT	1336
Db	1027	CTCGGCTCTTCCGACG-TGGGCTCCCTGCAGGCGCGCTGGGGAACCCATTGACCGGCT	1085
Qy	1337	GTA CTCCATGCAGAATTCTTACTTCACATCTTGA	1370
Db	1086	CTACTCCATGCAGAGCTCCTACTTTGCCTCCTGA	1119

SEQ ID NO:17 aligned with AF078166

Qy	1	TC---TGGCTTT-----TTCCACTTGGTGTGGT---GGT--TTGGGGAT--TCATTCA	43
Db	1119	TCAGGAGGCAAAGTAGGAGCTCTGCATGGAGTAGAGCCGGTCAATGGGGTTCCCCACGCG	1060
Qy	44	TTCCTATTTTCA GCATTCCACTGT--ATAGTCCAGAGGTGAGCAAG-GC-AAGGCTGGT--	97
Db	1059	CGCCTG---CAGGGAGCCACGTCGGAAGAGCCGAGG-AAGCAGTCGCTGAGGCTGGTGA	1004
Qy	98	GGGTGGCTCTGTTATCCATCTCCT-----GTGTCCAAGC-----GACTGC-	137
Db	1003	GGGAGGTATCACTATCAATATCGTGGAAGATGGAGTCGTTCCCTGGCATTGTTGGGGCGGCG	944
Qy	138	-----TCCAGTT-----GTCACCATGTTTCCAGT-----CACCAGGTGAGAGA	175
Db	943	TGAGGCCCTGTTGGAAGGGGTCGC--TGCTTCC-GTAGGGGCTCTGCTCCATGGCCACGA	887
Qy	176	GACTCTG--GCTGCAGA---GACAGGGCTGAGT-----GTC--CGTGTCGTCCAGGTGTG	223

Art Unit: 1649

Db 886 ---TCTGCTGCTGCGGAGGGGCCAGCGCGGTGTAGGAGGCCATCATGCCCTCCATGCGGC 830
Qy 224 GTTCCAAAACCAGAGAGCGAAG-----ATGAAGAAGCTGG---- 258
Db 829 TTGACAGAACCTCTTGGCCCAGCCGCTGGGAGTTCTGCTGCTCCTGCTGTTGCTGGTGTC 770
Qy 259 --CAGGCGACAGCAGCAGCAGC-----AGCAAGATCAGCAGAACACC 299
Db 769 TCCGGGC--CAGCTTCTTCATCTTTGCTCTTTGGTTCTGAAACCAGACCTG--GACCACA 714
Qy 300 CAGAGGCTGAG-----CTCTG-----CTCAGA-----CAAACGGTGGTGGGAG 337
Db 713 CGCACGCTGAGGCCTGTCTCTGCTGCCAATGTCTCTCGGACCTTCCGACAGGGCTTGGAG 654
Qy 338 -----TGCTGGGATGGAAGGA---ATCATGAA 361
Db 653 GAGACCTCAAAGGATGCCTTGAAAGCTCTTCGCTGCTGTGTGGTGAGGATGGTTCG-GGG 595
Qy 362 CC-----CCTACACGGCTC-TGCCC----ACCCACAGC-----AGCT--CCTG 398
Db 594 CCGTTTGGGCCTTCTCGGGTCTTTCCCGTCATCTCCACTGCCTTTACTCTGGCTGCCCTG 535
Qy 399 GCCAT---CGAGCAGAGTGTCTACAGC---TCAGATCCCTTCCGACAGGGTCTCACCCC 451
Db 534 CCCCTTGGCCGGCTTCATGTCTCCATCTTCATCCTCACTCTTC--ACAGAGTCAGACTCG 477
Qy 452 ACC-----CCAGATGC----CTGG-----AGAC--CACATG--CACCTTATGGTGC--C 491
Db 476 TCCGGGCTCACGGAGCTGAGCAGGTCTTTCTCCTTCTCATAGTACCCTTGCACAGCAGC 417
Qy 492 GAGCCCCTTTTCCATGACCTGGATAGCGACGACACCTCCCTCAGTAACCTGGGTGATTGT 551
Db 416 TGGCCC----TCCTTGAGCACGAACCTCGTC--CCCCTTGCAGTTCCT----- 373
Qy 552 TTCCTAGCAACCTCAGAAGCTG---GGCCTCTG-----CAGTCCAGAG-----T 592
Db 372 ---CTGCACACACAGCAGCAGAAACAGCCCAAGTGGTACACACACTCCAGCGCCCGCAT 316
Qy 593 GGGAAACCCCATTTGACCATCTGTACTCCATGCAGAATTCTTACTT---CAC----- 640
Db 315 GACGAACCTCGGTAGGCGCGATCTTCTCCATGCAGCCGCTGCACTTTGCCGCGAAGAGCTG 256
Qy 641 -----ATCTTG-----AGTCTTC---CCCTAGAGTT-----CTG----- 666
Db 255 TTGGTAGTCTTGTGTTGCAGTACAGTTTCCGATCCCGGAAGTAGCAGCTGGTGGTGAGGGC 196
Qy 667 ----TGACTAGGCTCCCATATGGAACA-ACCATATTCTTTGAGGGGTC----ACTGGCTT 717
Db 195 TTGCTGACATGCCGCGCACTGCAAACACTCCTCGTGCCAGGACGACTCGTTGACTCGCAT 136
Qy 718 TAGGA-----CAGGGAGGCCAGGGAAGAGGTGGGT--GGGGAG-- 754
Db 135 CAGGAAGCGGTGCGAGATGGGCCGCTGGCAGCCCTCGCAGACGGCGGGATGCGGGCAGTC 76

Art Unit: 1649

```

Qy      755 GGAGTTTTGTTG-----GGGATGCTGTTGTATAATGATATGGTGTAGCTCAGCATTT 806
          ||||  |  |          |||  ||  |  |  |  |  |  |  |  |  |  |
Db      75  GGAGCCCAGCAGCACCCCCAGGGTGGCGG--GCCCGGGGCGAAGGGCGTGCTCCTCCATC 18

Qy      807 CCAAAGACTGAATACAT 823
          |  |  |  |  |  |
Db      17 TTGATGCCGTCCAACAT 1

```

Smidt performed the assays on tissue slices, which comprise cellular samples, including the ventral midbrain; see for example Figure 1. The reference therefore teaches every element of claim 1. Furthermore, Smidt teaches the step of contacting the cellular samples with antibodies that bind to Ptx3 (see Figure 2d), anticipating claim 9.

Applicant argued that the amendment to recite certain specific hybridization conditions is sufficient to overcome the rejection. The examiner respectfully disagrees and notes that the three alignments shown above indicate that the sequences will hybridize. Note in particular the multiple long stretches of sequence identity in the first two alignments (i.e. SEQ ID NO:13 and 15). The USPTO does not have the resources to test the specific hybridization kinetics and parameters recited in the present claim. Given the large degree of sequence identity, the property of hybridization to applicant's recited SEQ ID NOs appears to be inherent to the nucleic acid used by Smidt. Absent evidence to the contrary (for example in the form of a declaration which shows that the prior art nucleic acids do not hybridize under the recited conditions) the property is presumed to be inherent. The reference anticipates each of claims 1 and 9.

Claim Rejections - 35 USC § 103

4. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later

Art Unit: 1649

invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 1, 9-10, and 12 are rejected under 35 U.S.C. 103(a) as being unpatentable over Smidt 2000 (Nature Neuroscience 3:337-341) in view of Holzs Schuh 2001 (Mechanisms of Development 101:237-243).

This rejection is maintained for the reasons previously made of record. The reasons why claims 1 and 9 are anticipated by Smidt are set forth above. Briefly, the reference teaches contacting a cellular sample with a nucleic acid that will hybridize to one or more of the nucleic acids listed in the claims to detect dopaminergic neurons, and also teaches detecting Ptx3 to confirm that a dopaminergic neuron is present. However Smidt does not teach detecting DAT as recited in claim 10 and 12.

Holzs Schuh teaches that DAT (dopamine transporter) is expressed in dopaminergic neurons, and that this marker can be used to distinguish truly dopaminergic cells from other catecholamine-containing cells. However Holzs Schuh does not teach the method of claims 1 or 9 or the product of claim 3.

It would have been obvious to one of ordinary skill in the art to modify the methods set forth by Smidt to include the steps taught by Holzs Schuh, thereby arriving at the invention recited in claims 10 and 12. Doing so would have been advantageous, Holzs Schuh teaches that DAT is particularly useful to identify dopaminergic neurons.

Applicant did not traverse the examiner's determination that the reference by Holzs Schuh renders obvious the specific limitations of claims 10 and 12. Rather applicant argued that the reference by Smidt does not teach the method recited in claim 9 or in part (a) of claim 12. The examiner respectfully disagrees, and notes that the reasons why Smidt teaches those particular limitations is set forth in the rejection under 35 USC 102(b) above.

Rejections Necessitated by Amendment

Claim Rejections - 35 USC § 103

5. Claims 1, 9, and 11 are rejected under 35 U.S.C. 103(a) as being unpatentable over Smidt 2000.

The reasons why claims 1 and 9 are anticipated by Smidt are set forth above. Not only does Smidt teach detection of nucleic acids that hybridize to SEQ ID NO:13, 15, and 17, the reference also teaches detection of Nurr1 in dopaminergic neurons; see for example Figure 5

Art Unit: 1649

and p. 338, second column, first complete paragraph. Therefore it would have been obvious to one of ordinary skill in the art to also detect Nurr1 as recited in claim 11. The motivation to do so would be to confirm that the detected neurons are in fact dopaminergic.

Conclusion

6. Claims 1 and 9-12 are rejected.
7. Claims 27-31 are allowed.
8. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

9. Any inquiry concerning this communication or earlier communications from the examiner should be directed to DANIEL KOLKER whose telephone number is (571)272-3181. The examiner can normally be reached on Mon - Fri 8:30AM - 5:00PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jeffrey Stucker can be reached on (571) 272-0911. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1649

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Daniel E. Kolker/

Primary Examiner, Art Unit 1649

March 18, 2010